Home infusion device maker KORU Medical reiterates 2026 outlook

Koru Medical Systems

06/05/2026 22:07

Overview

U.S. infusion solutions maker's Q1 net revenue grew 22% yr/yr to $11.8 mln

Net loss for Q1 improved 31% yr/yr to $0.8 mln

Gross margin fell to 61.5% due to higher production costs and tariffs

Outlook

KORU Medical reiterates 2026 net revenues guidance of $47.5 mln to $50.0 mln

Company maintains 2026 gross margin outlook of 61% to 63%

KORU Medical continues to expect positive adjusted EBITDA and positive cash flow for 2026

Result Drivers

DOMESTIC MARKET GAINS - Co said domestic core revenue rose due to higher consumable volumes, new patient starts and market share gains in new and existing accounts

INTERNATIONAL EXPANSION - Co said international core revenue grew due to higher pump and consumable volumes, driven by distributor purchases supporting pre-filled syringe conversions for a key EU market

PHARMA SERVICES GROWTH - Co said pharma services and clinical trials revenue increased due to higher clinical trial product revenues for advancing existing collaborations

HIGHER PRODUCTION COSTS AND TARIFFS - Co said gross margin fell due to higher production costs based on timing of production runs and tariff-related charges, partially offset by favorable geographic sales mix

Company press release: ID:nBw7ZJzYja

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$800,000
Q1 Gross Margin
61.50%
Q1 Operating Expenses
$8.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for KORU Medical Systems Inc is $7.00, about 71.6% above its May 5 closing price of $4.08

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)